Search Results

You are looking at 1 - 10 of 10 items for :

  • "biochemical relapse" x
Clear All
Full access

Eli Rosenbaum, Alan Partin and Mario A. Eisenberger

PSA era . Int J Radiat Oncol Biol Phys 2003 ; 57 : 915 – 928 . 5 Sylvester JE Blasko JC Grimm PD . Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle

Full access

Celestia S. Higano

therapy for prostate cancer, often called biochemical relapse . These men had no symptoms of cancer, yet were often treated with ADT because of concern for cancer progression. The side effects and toxicities of ADT became more apparent and assumed greater

Full access

.6004/jnccn.2004.0020 Prostate Cancer Clinical Practice Guidelines in Oncology 5 2004 2 2 3 3 224 224 224 224 10.6004/jnccn.2004.0021 Biochemical Relapse After Primary Treatment for Prostate Cancer: Studies on Natural History and Therapeutic

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Gary R. MacVicar, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Eric J. Small, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Patrick C. Walsh, Dorothy A. Shead and Maria Ho

without the express written permission of NCCN®. Biochemical Relapse The Canadian-led PR.7 trial provided the best phase III data to date comparing intermittent and continuous ADT in patients without metastasis. Crook et al 8 randomly assigned

Full access

David M. O’Malley

biochemical relapse and have no radiographic evidence of disease, recommendations include enrollment in a clinical trial, delaying treatment until clinical relapse, immediate platinum-based recurrence therapy (category 2B), or best supportive care. For

Full access

Shaji K. Kumar

/cyclophosphamide/etoposide/cisplatin (DCEP), and dexamethasone/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) with or without bortezomib. According to Dr. Kumar, the general principles of treating relapsed disease are (1) biochemical relapse does not always warrant

Full access

Philip J. Saylor and Matthew R. Smith

-recurrence. Biochemical relapses are generally identified years before disease would be clinically evident or radiographically visible. 14 Although PSA-recurrent disease often leads to initiation and long-term maintenance of ADT, this practice has not yet been shown

Full access

Matthew E. Nielsen, Bruce J. Trock and Patrick C. Walsh

remarkably consistent, showing an approximate halving of the risk for biochemical relapse with adjuvant RT ( Table 1 ). At a median follow-up of 10.9 years, the biochemical recurrence–free survival (BRFS) rates in SWOG 8794 were 64% for adjuvant RT versus 35

Full access

James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead and Maria Ho

progression-free survival and similar early toxicity (bladder, rectal, and quality of life) compared with standard radiation techniques. 108 - 114 According to a pooled analysis of phase II trials, the 5-year biochemical relapse-free survival rates are 95

Full access

James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski and Patrick C. Walsh

accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy . Urology 2005 ; 65 : 942 – 946 . 148. Stephenson AJ Shariat SF Zelefsky MJ . Salvage radiotherapy for recurrent prostate cancer